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ABSTRACT 
Objective: The aim of the present research was to improve dissolution of poorly soluble meloxicam a BCS (Biopharmaceutical Classification 
System) Class-II drug by utilizing liquisolid technique. Different liquisolid (LS) compacts were prepared using a mathematical model to calculate the 
required quantities of powder and liquid ingredients to produce acceptably flow able and compressible admixture. 
Methods: Liquisolid compact was prepared from; microcrystalline cellulose (Avicel PH 102) as carrier, colloidal silicon dioxide (Aerosil 200) and 
silica (cab-O-sil) as coating material, sodium starch glycol ate and cross povidon as superdisintegrants, PVP-K25 and HPMC E5 as additives to 
increase loading capacity, polyethylene glycol 400, propylene glycol and tween 80 as liquid vehicles. The ratio of carrier to coating material was 
kept constant in all formulations at 25:1, this ratio was chosen after testing the ratios 5:1, 10:1, 15:1, 20:1 and 25:1. The ratio 25;1 give optimal 
results relative to other ratios. 
The prepared LS compacts were evaluated for their tab letting properties. Fourier transform infrared (FTIR) analysis, differential scanning 
calorimetry (DSC), scanning electron microscope (SEM) and X-ray powder diffraction (XRPD) were performed. 
Results: The tab letting properties of the liquisolid compacts was within the acceptable limits. The drug release rates of the selected formulas (LS-3, 
LS-3A, LS-3AP and LS-3AH) of prepared liquisolid compacts were distinctly higher as compared to directly compressed tablets, and marketed 
tablets.  
The DSC, XRPD and SEM were suggested loss of meloxicam crystallinity upon liquisolid preparation indicating that even though the drug existed in a 
solid dosage form, it is held within the powder substrate in a solubilized, almost molecularly dispersed state, which may be contributed to the 
enhanced drug dissolution properties. 
The FTIR spectra showed disappearance of the characteristic absorption band of meloxicam (3290 cm-1
Conclusion: From this study it concludes that the LS technique is an effective approach to enhance the dissolution rate of meloxicam. 
) in liquidsolid formulation which might be 
attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. 
Keywords: Meloxicam, Liquisolid compacts, PEG 400, Dissolution rate. 
 
INTRODUCTION 
The poor dissolution rate of water insoluble drugs is still a 
substantial problem confronting the pharmaceutical industry. A 
great number of new and possibly, beneficial chemical entities do 
not reach the public merely because of their poor oral bioavailability 
due to inadequate dissolution. Over the years, various solid dosage 
formulation techniques, to enhance the dissolution of poorly soluble 
substances, have been introduced with different degrees of success. 
The technique of 'liquisolid compacts' is a new and promising 
addition towards such a novel aim. The active ingredient in a solid 
dosage form must undergo dissolution before it is available for 
absorption from the gastrointestinal tract. The poor dissolution 
characteristics of water-insoluble drugs are a major challenge for 
pharmaceutical formulation scientists. The absorption rate of a 
poorly water-soluble drug, formulated as an orally administered 
solid dosage form, is controlled by its dissolution rate in the fluid 
present at the absorption site, i. e. the dissolution rate is often the 
rate-determining step in drug absorption. Several researchers have 
shown that the liquisolid technique is the most promising method 
for promoting dissolution rate of poorly water-soluble drugs [1,2]. 
Liquisolid system is novel developed technique which involves 
conversion of liquid lipophilic drugs or water insoluble solid drugs 
dissolved in non-volatile solvent and this liquid medication can be 
converted into free-flowing, non adherent, dry looking, and readily 
compressible powders with the use of carrier and coating materials. 
In case of water soluble drugs, the sustained release can be obtained. 
"liquisolid system" is formulated by converting liquid lipophilic 
drugs, or drug suspensions or solutions of water-insoluble solid 
drugs in suitable non-volatile solvent systems, into "dry" (i. e., dry-
looking), nonadherent, free-flowing and readily compressible 
powder admixtures by blending with selected carrier and coating 
materials[3,4].  
MATERIALS AND METHODS 
Materials  
The following materials were used: Meloxicam (Sigma, Germany), Avicel 
PH 102 (FMC, USA), Aerosil 200 (Wacher HDK, Germany), Cab-O-Sil, SSG 
and Crosspovidon (Provizapharma, India), Propylene glycols (DOW, 
Germany), polyethylene glycol (PEG 400) (Chemfin chemical, india), 
Tween 80 (J. K. BAKAR, British), Methanol (ScharLab, Spain), Potassium 
dihydrogenortho-phosphate (BDH Chemicals, England), Magnesium 
stearate (Robert E. M. TILK, Germany) and Hydrochloric acid (BDH 
chemical, UK). All reagents used were of analytical grade. 
Methods  
Solubility studies  
To select the best non-volatile solvent for dissolving or suspending 
of meloxicam in liquid medication, solubility studies of meloxicam 
were carried out in PG, PEG 400 and Tween 80. Also SGF pH 1.2, and 
SIF pH 6.8 were used to study solubility behavior of meloxicam. 
Saturated solution were prepared by adding excess of meloxicam to 
the vehicles and shaking on the shaker for 48 hr under constant 
vibration. Then the solutions were filtered through a 0.45 mm 
Millipore filter, diluted and analyzed by UV-spectrophotometer 
(Specord, Japan). Three carried out for each sample to calculate the 
solubility of meloxicam. 
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Application of mathematical model for designing liquisolid 
system 
The flow ability and compressibility of liquisolid compacts are 
addressed simultaneously in the new formulation mathematical 
model of liquisolid systems, which was used to calculate the 
appropriate quantities of the carrier and coating materials required 
to produce acceptably flowing and compressible powders based on 
new fundamental powder properties called the flow able liquid 
retention potential (Φ -value) and compressible liquid retention 
potential (Ψ-number) of the constituent powders[5]. The flow able 
liquid retention potential of a powder is defined as the maximum 
amount of a given non-volatile liquid that can be retained inside its 
bulk (w/w) while maintaining acceptable flowability [6]. 
The compressible liquid retention potential (Ψ) of a powder is the 
maximum amount of liquid, the powder can retain inside its bulk 
(w/w) while maintaining acceptable compact ability, to produce 
compacts of suitable hardness and friability, with no liquid 
squeezing out phenomenon during the compression process. The Φ 
value of powders may be determined using a new procedure, the 
liquisolid flow ability (LSF) test. The Ψ number of powders may be 
determined using a new method termed the liquisolid 
compressibility (LSC) test which employs the 'pactisity theories' to 
evaluate the compaction properties of liquid/ powder 
admixtures[5]. According to the new theories, the carrier and 
coating powder materials can retain only certain amounts of liquid 
while maintaining acceptable flow and compression properties. 
Depending on the excipients ratio (R) or the carrier: coating ratio of 
the powder system used, Where, 
R = Q/q(1) 
As R represents the ratio between the weights of carrier (Q) and 
coating (q) materials present in the formulation. An acceptably 
flowing and compressible liquisolid system can be prepared only if a 
maximum liquid on the carrier material is not exceeded; such a 
characteristic amount of liquid is termed the liquid load factor (Lf) 
and defined as the ratio of the weight of liquid medication (W) over 
the weight of the carrier powder (Q) in the system, which should be 
possessed by an acceptably flowing and compressible liquisolid 
system. i. e. 
Lf = W/Q(2) 
The powder excipients ratios R and liquid load factors Lf of the 
formulations is related as follows:  
Ψ Lf =Φ+ Φ(1/R)(3) 
In order to calculate the required ingredient quantities, the flow able 
liquid retention potentials (Φ-values) of powder excipients were 
utilized. So to calculate the required weights of the excipients used, 
first, from Eq. (3), Φ and Φ and are constants, therefore, according to 
the ratio of the carrier/ coat materials (R), Lf was calculated from 
the linear relationship of Lf versus 1/R. Next, according to the used 
liquid vehicle concentration, different weights of the liquid drug 
solution (W) will be used. So, by knowing both Lf and W, the 
appropriate quantities of carrier (Q) and coating (q) powder 
materials required to convert a given amount of liquid medication 
(W) into an acceptably flowing and compressible liquisolid system 
could be calculated from equations (1) and (2). 
Preparation of directly compressible tablet (DCT) and liquisolid 
compact 
Directly compressible tablets (DCT) of meloxicam were prepared by 
direct compression using single tablet punch machine, each 
containing 15 mg meloxicam, 149 mg Avicel PH 102, 10 mg Aerosil 
200, 5 % w/w sodium starch glycol ate as superdisintegrant, 20 mg 
PVP K25 and 1 % w/w magnesium stearate. Various LS compacts 
denoted (LS-1 to LS-3AH) containing 15 mg of meloxicam were 
prepared by dispersing in non-volatile vehicles (PG, PEG 400 and 
Tween 80).Then a bindery mixture of carrier of carrier (Avicel PH 
102) and coating material (Aerosil 200 or Silica Cab-O-Sil) was 
prepared at a ratio of 25: 1 (trial and error methods were used, i. e. 
changing the carrier: coating material ratio (R) from 5, 10, 15, 20 
and 25, until get good result (flow properties) is obtained. R 25 was 
used in all formulations since it gave the optimal flow property. 
This binary mixture was added to the admixture of drug and vehicle. 
Finally 5 % SSG as disintegrant was added in above powder blend 
and mixed in all formulas except formula LS-3B which used 
crosspovidon. The final powder blend was subjected to compression. 
Precompression studies of the prepared liquisolid powder 
system 
Differential scanning calorimetry (DSC)[7] 
DSC was performed in order to assess the thermo tropic properties 
and thermal behavior of pure meloxicam, Avicel PH 102, DCT and 
the liquisolid compact. DSC measurement performed on DSC 60 
Shimadzu, Japan. Thermal behavior of the samples was investigated 
under a scanning rate of 10°C/min, covering a temperature range of 
30 to 300°C under inert atmosphere flushed with nitrogen. 
Fourier transform infrared spectroscopy (FTIR)[7] 
Compatibility studies of pure drug and excipients were carried out using 
Fourier transformed infrared spectrophotometer (Shimadzu, Japan) in 
the range of 400-4000/cm by KBr disc method. A base-line correction 
was made using dried potassium bromide and then the spectrum of the 
pure meloxicam, DCT and liquisolid system were obtained. 
X-ray diffractometery (XRD) 
For characterization of the crystalline state, the X-ray diffraction 
(XRD) patterns are determined for drug meloxicam, excipient and 
for the prepared liquisolid system [8]. 
The results were recorded over a range of 0-50° (2θ) using the Cu-
target X-ray tube and Xe-filled detector. The operating conditions 
were: voltage 40 kV, current 30 mA, scanning speed 1/min [9], using 
Philips Analytical (PW3710). 
Scanning electron microscopy (SEM) 
SEM is utilized to assess the morphological characteristics of the raw 
materials and the drug-carrier systems. The samples were fixed on 
aluminum stubs with double-sided tape, gold-coated sputter and 
examined in the microscope using an accelerating voltage of 15 kV at 
a working distance of 8 mm [10]. 
The photomicrographs of pure meloxicam and liquisolid system 
were performed using VEGA easy probe (Germany) scanning 
electron microscopy. 
Flow properties of liquisolid system  
The flow ability of powder is of critical importance in the production 
of pharmaceutical dosage forms in order to get a uniform feed as 
well as reproducible filling of tablet dies otherwise high dose weight 
variations will occur. 
Evaluation of Meloxicam Liquisolid Tablets 
Friability and hardness tests 
The friability test was done using Erweka friabilitor for 4 minutes at 25 
rpm using 20 liquisolid tablets for each formula, weighing them all 
together (W initial) then placing all of them inside the friabilitor. After 
their revolution, they were clean from dust and weighed again (W final). 
The friability was calculated as the percentage according to equation 
(10)[11]. 
%Friability = (W initial- W final) / W initial x 100 %. (10) 
The hardness of 3 tablets from each of the prepared formulas was 
measured individually. An anvil driven by electric motor presses the 
tablet at a horizontal position and constant load until the tablet 
breaks [12]. The hardness was measured in terms of kg using 
hardness tester TBH 100 (Erweka, Germany). 
Content uniformity 
Drug content was assessed for five randomly selected tablets. The 
tablets were crushed and total content of the five tablets was mixed 
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thoroughly. powder containing 15 mg of meloxicam was dissolved in 
10 mL of methanol and volume was adjusted to 100 mL with pH 6.8 
buffer. The solution was then filtered, and from this solution 1 mL 
was taken and phosphate buffer (pH 6.8) was added to complete the 
volume to 100 mL in standard volumetric flask. The amount of drug 
present in each tablet was determined spectrophotometrically at 
360 nm using UV- spectrophotometer. The same procedure was 
followed for all the prepared formulas[13]. 
Disintegration test 
The disintegration test was performed at 37±0.5 °C in 0.1N HC1(pH 
1.2) for three tablets from each formula and three capsules from 
encapsulated formulas (LS3-A, LS-3AP and LS-3AH) using the USP 
tablet disintegration apparatus (Disintegration tester ZT 322, 
Erweka, Germany). The tablets were considered completely 
disintegrated as no residue remains on the screen. Generally, ideal 
tablet hardness should be produced without applying excessive 
compression force where rapid tablet disintegration and drug 
dissolution are maintained at the same time[9]. 
In-vitro dissolution studies of liquisolid tablets 
The dissolution study was carried out using USP apparatus 1 paddle 
for the tablets and apparatus 11 basket for the capsules. The 
dissolution test was used to compare between liquisolid tablets, 
DCT, and marketed meloxicam tablet (mobic). And then compare the 
selected liquisolid formula with the same formula but in 
encapsulation form. 
The dissolution media were either 900 mL of SGF 0.1 N HCl pH 1.2 
and SIF phosphate buffer pH 6.8, at 37 ± 0.5 ͦ C, Meloxicam tablet and 
capsule were kept in the paddle and basket dissolution apparatus 
respectively, at 50 rpm. Sample of 5 mL were withdrawn at specific 
time intervals (5, 10, 20, 30, 45, 60 min) and filtered through a 0.45 
µm filter then analyzed spectrophotometrically at 344 nm and 360 
nm for HCl pH 1.2 and phosphate buffer 6.8, respectively (using 
Copley dissolution 8000 tester, Copley scientific, UK). The samples 
withdrawn were replaced by fresh buffer solution to maintain 
constant volume. Each preparation was tested in triplicate and the 
mean value were calculated [14]. 
Statistical Analysis 
The results of the experiments are given as a mean of triplicate 
samples ± standard deviation and were analyzed according to the 
one-way analysis of variance (ANOVA) at the level of (P < 0.05). 
RESULTS AND DISCUSSION  
Solubility studies 
The solubility of MLX in different solvents is listed in table (1). As 
shown in the table, its solubility is very poor in 0.1 N HCl (pH 1.2) 
0.1939 mg/ ml. phosphate buffer solution, pH 6.8, enhanced the 
solubility of MLX to the level of 0.5790 mg/ ml, due to partial 
ionization of the drug at this pH. In propylene glycol (PG), the 
solubility of MLX was found to be 0.3489 mg/ ml, which is slightly 
greater than that of HCl. This slight increase is probably through 
hydrogen bonding. Meloxicam solubility in PEG was 40 fold higher 
than HCl 7.0014. PEG, with a large nonpolar part and several 
hydroxyl groups is responsible for the enhanced solubility. Thus, 
among the solvents tested, PEG 400 could be a better choice as 
asolvent[15]. Tween 80 also enhanced the solubility of meloxicam 
0.3907, indicating the micellar solubilization in concentration higher 
than its cmc. This suggested the nonpolar nature of MLX and its 
presence in the hydrophobic interior of the micelle [16]. 
The table also shows that an increase in pH resulted in an increase in 
the solubility of MLX; this is because MLX is acidic[17]. 
 
Table 1: Solubility of MLX in various solvents 
Solvent/ vehicle Solubility(%w/w) 
SGF (pH 1.2) 0.1939 
SIF (pH 6.8) 0.5790 
PG 0.3489 
PEG 400 7.0014 
Tween 80 0.3907 
 
Application of Mathematical Model for Designing the Liquisolid 
Systems 
Meloxicam has poor aqueous solubility and wet ability, and exhibits 
poor dissolution in aqueous fluids especially in acidic medium. Such 
property poses difficulties not only in the design of pharmaceutical 
formulations but also results in biovariability. It is an ideal candidate 
for testing the potential of rapid-release liquisolid compact [18]. In 
order to calculate the required ingredient quantities, the flowable 
liquid retention potentials (Ф-values) of powder excipients were 
utilized. In PEG 400, the Ф-values of Avicel PH 102 and Aerosil 200 
(or silica) were found to be 0.005 and 3.26 respectively[4]. On the 
other hand, in PG, the Ф-values of Avicel PH 102 and Aerosil 200 (or 
silica) were found to be 0.16 and 3.31 respectively[19]. 
While, In Tween 80, the Ф-value of Avicel PH 102 was found to be 
0.16, while for Aerosil 200 the Ф-value used was equal to 3.33[20]. 
Mathematical model equations for Avicel PH 102 and Aerosil 200 (or 
silica) in PEG, PG and Tween 80 express according to values of Ф as 
given by spire as et al[4, 5]as follow:  
Lf =0.005+ 3.26 (1/25) for PEG 400 
Lf =0.16 +3.31 (1/25) for PG 
Lf =0.16 + 3.33 (1/25) for Tween 80  
For R-value used 25, the corresponding Lf value can be calculated. As 
soon as the optimum liquid load factor of a given excipients ratio is 
established for each formula and W is calculated according to MLX 
concentration in liquid vehicle, the appropriate quantities of Avicel PH 
102 (Qo) and Aerosil 200 (qo) required to convert a given amount of 
liquid medication (W) into an acceptably flowing and compressible 
liquisolid system, were calculated using Eqs. (1) and (2). The amount 
of superdisintegrant is equal to 5% of the tablet weight. Table 2 and 
3 represents the exact qualitative and quantitative composition for 
each formula. 
 






































LS-1 PEG 15  25 0.135 85 15 740.7 29.6 43.5 913.8 
LS-2 PEG 22.5 25 0.135 51.6 15 493.3 19.7 28.9 608.5 
LS-3 PEG 30 25 0.135 35 15 370.3 14.8 21.7 456.8 
LS-4 PG 15 25 0.292 85 15 342.4 13.6 22.8 478.8 
LS-5 PG 22.5 25 0.292 51.6 15 228 9.1 15.1 318.8 
LS-6 PG 30 25 0.292 35 15 171.2 6.8 11.4 239.4 
LS-7 TW 80 15 25 0.293 85 15 341.2 13.6 22.7 477.5 
LS-8 TW80 22.5 25 0.293 51.6 15 227.3 9.09 15.1 318.1 
LS-9 TW 80 30 25 0.293 35 15 170.6 6.82 11.3 238.7 
Table 3: Composion of meloxicam liquisolid formulas prepared by using PEG 400 as liquid vehicle 
Altememy et al. 
















































LS-1 A PEG  15 25 0.135 85 15 740.7 29.6 SSG  913.8 
LS-2 A PEG 22.5 25 0.135 51.6 15 493.3 19.7 SSG  608.5 
LS-3 A PEG 30 25 0.135 35 15 370.3 14.8 SSG  456.8 
LS-3 B PEG 30 25 0.135 35 15 370.3 14.8 Crosspovidon  456.8 
LS-3 A P PEG 30 25 0.135 35 15 370.3 14.8 SSG PVP–K 25 502.4 
LS-3AH PEG 30 25 0.135 35 15 370.3 14.8 SSG HPMC E5 502.4 
 
Precompression Studies of the prepared liquisolid powder systems 
As the angle of repose (θ) is characteristic of the internal friction or 
cohesion of the particles, according to USP values, the value of the 
angle of repose will be high if the powder is cohesive and low if the 
powder is non-cohesive [21]. 
From the result show in table (4), conclude that, the increase in 
concentration of drug in vehicle (LS -1, LS-2 and LS-3 in PEG 400) 
and (LS-4, LS-5 and LS-6 in PG) cause reduction in the angle of 
repose and increase in flow ability of formula. Whereas, decrease in 
concentration of liquid vehicle used lead to increase in flow ability 
and decrease in angle of repose. 
While, in (LS-7, LS-8 and LS-9 in Tween 80) show poor flow ability 
and in all concentration, may attributed to that tween 80 is poor 
liquid vehicle for meloxicam liquisolid system due to solubility of 
drug in that vehicle.  
So, any formula which have poor flow were cancelled and not 
followed for further evaluation such as LS-4, LS-7, LS-8 and LS-9. 
The formulas LS-1A, LS-2A and LS-3A show better flow ability than 
corresponding formulas LS-1, LS-2 and LS-3, this attributed to that 
silica (cab-O- sil) have good result in coating properties which lead 
to increase the flowbility and decrease the angle of repose, in spite of 
have similar surface area as Aerosil 200.  
The formula LS-3B show increase in the angle of repose slightly than 
corresponding formula LS-3, due to nature of crosspovidon used 
which have low flow ability than sodium starch glyconate. 
Both formula LS-3AP and LS-3AH show increase the flowbility and 
decrease the angle of repose corresponding to the formula LS-3A, 
this may be due to the usage of the PVP- K25 and HPMC E 5 to 
produce the micro system.  
Also, these additives cause increase in the loading capacity of the 
carrier to liquid medication resulting in free flowble formula better 
than corresponding one. The formula of DCT give good flow ability.  
The Carr's compressibility index and Hausner's ratio are measurements 
to find out tendency of powders to be compresse [22]. 
Formulas LS-1, LS-2, LS-3, LS-5, LS-6, LS-1A, LS-2A, LS-3A, LS-3B, LS-
3AP, LS-3AH and DCT exhibited good flow, while the flow of the 
remaining liquisolid formulas were fair as show in table 4. 
As presented in table (4), the formulas of the higher drug 
concentration in liquid vehicle showed lower Carr s̓ index and 
Hausner ҆s ratio (better flow ability) than the formulas of lower 
concentration. 
Also the formulas LS-3AP and LS-3AH have lowest angle of repose, 
Carr ҆s index and Hausner ҆s ratio due to effect of additive (PVP and 
HPMC) which leade to increase the loading capacity of drug and give 
good flow ability. 
Beside, the formulas of PEG as liquid vehicle better than PG, and 
these two are better than tween 80 as liquid vehicle, indicated that 
PEG is better solvent to MLX liquisolid system.  The DSC showed the 
thermal behaviors of the pure components together with the 
thermal behavior of the final liquisolid system [23]. 
Figure (1) showed the thermal behaviors of the pure meloxicam. The 
MLX peak is clear, demonstrating a sharp characteristic endothermic 
peak at 260 °C corresponding to its melting temperature. Such a 
sharp endothermic peak shows that the MLX used was in a pure 
crystalline state[24]. 
The thermo grams of Avicel PH 102 (figure 2) displayed a broad 
endothermic peak at 48.12°C, which might correspond to 
volatilization of the adsorbed water followed by melting 
decomposition with charring of the crystalline cellulose type 
material [23]. 
The thermo gram of DCT (figure 3) exhibited endothermic peak at 
250°C, which is the peak of the drug, indicated that there is no 
interaction between the drug and excipients used in the formulation 
and the drug still in the crystalline form[22]. 
On the other hand, the liquisolid system (figure 4) showed that the 
characteristic peaks of MLX disappeared, this agrees with the 
formation of a solid solution in the liquisolid powdered system, i. e., 
the drug was molecularly dispersed within the liquid vehicle[25]. 
This disappearance of drug peaks upon formulation into a liquisolid 
system was in agreement with McCauley and Brittain[26 ]who declared 
that the suppression of all drug thermal features undoubtedly indicates 
the formation of an amorphous solid solution. In addition, Mura et al [27] 
found out that the disappearance of the drug melting peak indicates that 
drug amorphization had taken place. 
The spectrum of pure MLX was represented in figure 15 and showed 
the characteristic peaks of the drug at[28]: N-H stretching: 3290.33 
cmP-1P, C-H stretching: 2966.62 cmP-1P, S=O stretching: 1043.42 cmP-1P, C=O 
stretching: 1618.17 cmP-1 
Figure 6showes the FTIR spectrum of physical mixture (DCT) values 
as follows: N-H stretching: 3294 cmP-1P, C-H stretching: 2976 cmP-1P, S=O 
stretching: 1098 cmP-1P, C=O stretching: 1670 cmP-1 
There is no different between figure 5 and 6 in pure drug and DCT of 
the characteristic peaks of FTIR. Indicating that there was no 
interaction between drug-excipients used in the study and no 
hydrogen bond formation in DCT. 
It is observed that the peaks of major function groups of MLX, which 
are present in spectrum of pure drug, were present in MLX liquisolid 
formula (figure 7) but the broadness of the characteristic peak of 
MLX with shifting to lower frequency might be due to formation of 
hydrogen bonding between the carboxylic group of MLX and the 
hydroxyl group of the PEG in liquisolid formula, this resulted in drug 
dissolution enhancement [29]. 
The crystallinities of pure MLX, excipients and liquisolid system 
were evaluated by XRD measurement. It has been seen that 
polymorphic changes of the drug are important factors, which may 
affect the drug dissolution rate and bioavailability[9]. The XRD 
results were in good agreement with the thermal analysis data. The 
X- ray diffract gram of pure MLX (figure 15) exhibited several sharp 
peaks at different angle (2Ɵ)  13.0Ɵ, 15.0Ɵ, 18.5Ɵ, 19.0Ɵ, 20.5Ɵ and 
26.0Ɵ suggested that the drug existed as crystalline material [30]. 
The liquisolid powder X-ray diffraction pattern in figure 10 showed 
only one sharp diffraction peak at 2Ɵ angle of 22.5 belonging to 
Avicel PH 102 (figure 9), indicating that only Avicel PH 102 
maintained its crystalline state[10]. Such absence of MLX specific 
peaks in the liquisolid X-ray diffract grams indicates that MLX has almost 
entirely converted from crystalline to amorphous or solubilized form, 
such lack of crystallinity in the liquisolid system was understood to be as 
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a result of drug solubilization in the liquid vehicle (PEG 400) i. e., the 
drug has formed a solid solution was absorbed into and adsorption onto 
the carrier Avicel PH 102. This X-ray data supported that the MLX 
formed a solid solution with in the carrier matrix. The amorphization or 
solubilization of drug in the liquisolid system may cause the marked 
improvement in the solubility and therefore the dissolution rate of the 
drug [31]. Morphological characteristics of drug and powder mass of 
liquisolid system were analyzed using SEM [30]. 
Figure 11 illustrated the photomicrograph of the pure drug (MLX). It 
showed the drug had crystalline nature as was proved previously by 
the DSC and XRD. 
The photomicrograph of the liquisolid system showed the complete 
disappearance of MLX crystals (figure 12). Thereby supporting the 
transformation of drug from the crystalline to the amorphous state, 
this fact indicates that even though the drug is in solid dosage form, 
it is held within the powder substrate in solution or in solubilized, 
almost molecularly dispersed state which contributes to enhance 
drug dissolution property [32]. 
 
Table 4: flow ability parameters of MLX liquisolid powder systems. 
LS system code Angle of repose θ ± S. D.* Compressibility% ±S. D.* Hausner's ratio±S. D.* 
LS- 1 33.6 ± 0.528 11.62±0.396 1.131±0.012 
LS- 2 33 ± 0.337 13.6±0.452 1.156±0.01 
LS- 3 29 ± 0.5323 11.89±0.384 1.136±0.012 
LS- 4 39.2 ± 0.649 16.3±0.473 1.2±0.011 
LS- 5 34.5 ± 0.584 14.68±0.447 1.172±0.011 
LS- 6 31.14 ± 0.482 12.24±0.357 1.14±0.011 
LS- 7 Not flow 24.02 ± 0.302 1.302 ± 0.01 
LS- 8 47 ± 0.334 24.53 ± 0.233 1.32 ± 0.01 
LS- 9 45 ± 0.412 23.22 ± 0.3 1.28 ± 0.01 
LS- 1A 32.8 ± 0.263 14.64 ± 0.495 1.167 ± 0.01 
LS- 2A 30.7 ± 0.873 12.61±0.411 1.146±0.01 
LS- 3A 26.5 ± 0.742 14.65 ± 0.299 1.172 ± 0.02 
LS- 3B 30.73 ± 0.732 14.53 ± 0.412 1.14 ± 0.011 
LS- 3AP 24.3 ± 0.437 11±0.145 1.123±0.01 
LS- 3AH 25 ± 0.623 11.1±0.262 1.125±0.01 
DCT 28.1 ± 0.774 15.24±0.471 1.179±0.011 




















































Fig. 4: DSC thermogram of MLX liquisolid system 
Altememy et al. 




Fig. 5: FTIR spectrum of pure MLX 
 
 
Fig. 6: FTIR spectrum of DCT 
 
 
Fig. 7: FTIR spectrum of MLX liquisolid system 
 
 
Fig. 8: X-ray diffraction of pure MLX 
 
Fig. 9: X-ray diffraction of Avicel PH 102 
 
 
Fig. 10: X- ray diffraction of MLX liquisolid system. 
 
 
Fig. 11: SEM of pure drug MLX 
 
 
Fig. 12: SEM of liquisolid compact 
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Evaluation of meloxicam LiquisolidTablets 
Friability and hardness tests 
All MLX liquisolid tablets exhibited acceptable friability as none of 
the tested formula had percentage loss in tablets weights that exceed 
1%, also, no tablet was cracked, split or broken in all formulas. Since 
all the prepared formulas met the standard friability criteria, they 
are expected to show acceptable toughness and withstand abrasion 
during handling, packaging and shipment [ 29]. 
In general, formulation should be directed at optimizing tablet 
hardness without applying excessive compression force, while at the 
same time assuring rapid tablet disintegration and drug dissolution. 
In other words, tablets should be sufficiently hard to resist breaking 
during normal handling and yet soft enough to disintegrate properly 
after swallowing [33]. The mean hardness of each liquisolid 
formulas was determined and is presented in table (5) proving that 
all the liquisolid tablet formula had acceptable hardness. 
The compactness of tablets may be due to hydrogen bonding 
between Avicel PH 102 molecules [34]. Avicel PH 102 
compressibility and compactness characteristics can be explained by 
the nature if crystalline cellulosic particles themselves which are 
held together by hydrogen bonds which when compressed, are 
deformed plastically and a strong compact is formed due to the 
extremely excessive number of surfaces brought into contact during 
the plastic deformation, and the strength of the hydrogen bonds are 
formed[10]. In addition, both PG and PEG 400 molecules contain two 
terminal hydroxyl groups, thus there is also a probability of forming 
hydrogen bonds with Avicel PH 102[35]. 
It was seen that as the amount of Avicel goes on increasing, hardness 
also increases. This low hardness could be attributed to the less 
amount of added Avicel and poor compressibility of Aerosil [36]. 
The disintegration time for the prepared MLX liquisolid tablets and 
capsule was shown in table (5). It was found that, the mean of the 
disintegration times for all investigated tablets were less than 2 
minutes(except for LS-3B), which fulfill the pharmacopoeial 
requirement. Also the capsule prepared showed disintegration time 
between 25- 35 minutes. LS-3AP, LS-3AH and LS-1 showed short 
disintegration time (38, 43 and 52 second; respectively). whileLS-
3B, LS-3 and LS-3A showed the slowest disintegration time that 
equal to 1500, 82 and 78 second; respectively. These results can be 
explained as increasing the amount of liquid used in formulas with 
short disintegration time and significantly increased wetting 
properties and surface area of the drug and increasing the 
availability of the drug to be easily disintegrated from its solution or 
suspension, and this subsequently; decrease the disintegration time 
of the tablets. Also high Avicel PH 102 content where Avicel PH 102 
functions as a swell able disintegrant [37]. 
In addition, the highly hydrophilic characteristic of Avicel PH 102 
could increase the wetting of MLX and this subsequently, lead the 
tablet to be disintegrated quickly and decreased the disintegration 
time of the tablets [38]. 
Moreover, the disintegration time for DCT was approximately less 
than 7 minutes, while for capsules prepared from liquisolid formulas 
(LS-3A, LS-3AP and LS-3AH) showed 30, 35 and 28 minutes; 
respectively. 
Be sided, the use of superdisintegrant (sodium starch glycol at) 
accerlated the disintegration of the tablets by virtue of its ability to 
absorb a large amount of water when exposed to an aqueous 
environment[39]. 
From the table 5 of disintegration time showed SSG better 
disintegrant than crosspovidon. 
 
Table 5: Hardness, Friability and disintegration percentage of MLX liquisolid formulation 
LS system cod Hardness (Kg/cmP2 P)±S. D.* N=3 % Friability (W/W) Disintegration time (sec) Mean ± S. D. n=3 
LS-1 6.39 ± 0.22 0.23 52 ± 4.23 
LS-2 6.13 ± 0.24 0.33 72 ± 4.1 
LS-3 5.93 ± 0.54 0.42 82 ± 3.12 
LS- 5 5.57 ± 0.33 0.46 73 ± 4.47 
LS-6 5.41 ± 0.55 0.29 77 ± 4.6 
LS-1A 6.2 ± 0.44 0.38 58 ± 3.26 
LS-2A 6.15 ± 0.34 0.27 72 ± 3.11 
LS-3A 6.10 ± 0.31 0.38 78 ± 3.42 
LS-3B 6.27 ± 0.37 0.44 1500 ± 4.48 
LS-3AP 6.41 ± 0.42 0.40 38 ± 2.28 
LS-3AH 6.28 ± 0.43 0.35 43 ± 3.58 
LS-3A CAP   1800 ± 5.2 
LS-3AP CAP    2120 ± 6.86 
LS-3AH CAP   1680 ± 7.09 
DCT   385 ± 6.86 
 
Content uniformity 
The drug content of the prepared liquisolid tablets were found to be 
in the range of 92 -101 % which is due to acceptable uniformity of 
content of prepared liquisolid tablets. 
In-vitro dissolution studies 
In-vitro drug release studies were performed in two different 
dissolution media (0.1N HCl pH 1.2 and phosphate buffer pH 6.8) for 
the prepared liquisolid formulas and were compared with that of 
DCT and marketed tablet.  
The graphs showing drug release profile for all formulas were 
shown in the figures 13, 14, 15, 216 and 17. 
The percent of MLX released from liquisolid compacts containing 
varying amounts of carrier and coating material (from LS-1 to LS-6) was 
found to vary from 30.38 % to 80.38 % in 0.1N HC1 (pH 1.2) and from 
56.10 % to 81.16 % in phosphate buffer (pH 6.8) in the first 20 min 
(figures 13). 
All the formulas of liquisolid compact prepared with PEG solvent 
showed better release than PG prepared liquisolid compact, due to 
fact that the solubility of MLX higher in PEG than PG as show in table 
(1), so the preparation of MLX liquisolid compact good with the PEG 
solvent. 
The percent of MLX released from formula LS-3B is low 
corresponding to formula LS-3 which replaced the SSG with 
crosspovidon as superdisintegrant, this attributed to the 
disintegration time of formula LS-3B slower than LS-3, so the release 
slower than liquisolid formula LS-3,as show in figure 14. 
The formulas LS-1A, LS-2A and LS-3A showed higher percent release 
of MLX in first 20 minutes corresponding to LS-1, LS-2 and LS-3, this 
attributed to coating effect which related to used the silica (Cab-O-
sil) instead of Aerosil, which indicate that silca is good coating 
material than Aerosil which facilitate the release drug fastely than 
Aerosil. Unless, these tow coating material have same surface area, 
as showed in figure 14. 
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The used of additives PVP and HPMC gave the formula release of 
drug higher than other formula in first 20 minutes. This showed in 
formulas LS-3AP and LS-3AH, this attributed to increase the loading 
efficiency of the drug through the carrier Avicel that related to used 
additives, as show in figure 15. 
The comparism of selected formula LS-3A, LS-3AP and LS-3AH with 
corresponding same formulas but, encapsulated in shell capsule by 
dipping method showed that release profile of MLX from the 
liquisolid tablets was higher and faster than same formula in capsule 
form. This attributed to that disintegration time of tablet occur with 
seconds to few minutes than capsules which need more than 25 
minutes to opening of shell of capsule and then release its content 
slowly until complete rupture of the shell and release its content to 
media, as show in figures 16, 17 and 18. 
All the liquisolid batches derivative from LS-3 (LS-3, LS-3A, LS-3AP 
and LS-3AH) showed higher drug release profile than the DCT and 
the marketed tablet. The enhanced dissolution rates of liquisolid 
compacts compared to DCT and marketed tablet may be attributed 
to the fact that the drug is already in solution in PEG, while at the 
same time it is carried by the powder particles (microcrystalline 
cellulose and silica)[8]. 
In essence, after disintegration, the liquisolid primary particles 
suspended in the dissolving medium contain the drug in a 
molecularly dispersed state, whereas the directly compressed 
compacts are merely exposed micronized drug particles. Therefore, 
in the case of liquisolid compacts, the surface area of drug available 
for dissolution is much greater than that of the directly compressed 
compacts [40], as show in figure 15. 
According to Noyes and Whitney [41], the drug dissolution rate (Dr
Thus, its release is accelerated due to its markedly increased wet 
ability and surface area available to the dissolution medium. The wet 
ability of the compacts by the dissolution media is one of the 
proposed mechanisms for explaining the enhanced dissolution rate 
from the liquisolid compacts [42]. 
) 
is directly proportional not only to the concentration gradient (Cs-C) 
of the drug, but also to its surface area (S) available for dissolution (e 
q 4). Moreover, since all dissolution tests for MLX preparations were 
carried out at a constant rotational paddle speed (50rpm/min) and 
identical dissolving media, it is assumed that the thickness (h) of the 
diffusion layer and the diffusion coefficient (D) of the drug molecules 
transported through it remain almost identical under each set of 
dissolution conditions. Therefore, the significantly increased 
effective surface area of the molecularly dispersed MLX in the 
liquisolid compacts may be principally responsible for their 
observed higher dissolution rates [29]. 
The consistent and higher dissolution rate displayed by liquisolid 
compacts will improve the absorption of drug from the GIT[43]. 
Dr= {D x S x (C s
Where, 
 - C)}/ h e q (4) 
Dr
S = Surface area available for dissolution. 
= Rate of dissolution. 
D = Diffusion coefficient of the compound. 
Cs = Concentration of the drug in the diffusion layer. 
C = Concentration of drug in the dissolution medium at time t. 
h = Thickness of the diffusion boundary layer adjacent to the surface 
of the dissolving compound[44]. 
From drug release profiles, it was found that the formula LS-3 
(higher drug concentration in PEG) showed the highest drug release 
when compared to the formulas LS-1, LS-2, LS-5 and LS-6, while the 
formula LS-5 (lower drug concentration in PG) had lowest release 
profile among these above liquisolid formulas. 
Also, when replaced the Aerosil 200 coating material with Silica give 
higher result in release profile as showed in formulas LS-1A, LS-2A 
and LS-3A. The release of LS-3B formula showed lower than 
corresponding LS-3 due to disintegration time of superdisintegrant. 
Beside, it can be concluded from figure 15 that the percentage drug 
release is increase with used of additives PVP K-25 and HPMC as 
show in formulas LS-3AP and LS-3AH.  
In figure (15), the optimized formulation (LS-3A, LS-3AP and LS-
3AH) was compared with marketed tablet and DCT. The results 
showed that there was no significant different (P > 0.05) between 
the release profile of these formulas with both DCT and marketed 
tablet in both dissolution media. 
The percentage drug release (MLX) in 20thmin from DCT and 
marketed tablets were: 53.14 % and 61.64 %, respectively in 0.1 N 
HCl (pH 1.2);77.89 % and 75.98 %, respectively in phosphate buffer 
(pH 6.8). while the percentage drug release of MLX in 20th
Variables Affecting the Dissolution Rate of meloxicam Liquisolid 
Tablets 
 min. from 
LS-3, LS-3A, LS-3AP and LS-3AH showed 80.28, 84.95, 90.96 and 
94.58 %, respectively in 0.1 N HCl (pH1.2); and 81.16, 89.92, 92.01 
and 94.82 %, respectively in phosphate buffer (pH 6.8) (figures 13, 
14 and 15). This is because, in the case of liquisolid tablets, the 
surface of drug available for dissolution is related to its specific 
molecular surface which by any means, is much greater than that of 
MLX particles delivered by the plain or directly compressed tablets. 
Significantly increased effective surface of the molecularly dispersed 
MLX in the liquisolid tablets may be chiefly responsible for their 
observed higher and consistent drug dissolution rates[33]. 
The effect of liquid vehicle type 
As shown in table (1),MLX has a higher solubility in PEG 400 
compared to PG; therefore, the liquisolid tablets formulated with 
PEG 400 (LS-3 or its derivatives) should have a better dissolution 
rate than those formulated with PG (LS-5 and LS-6)[32,45,46]. Its 
clearly shown in figure (134) that first 20 min., MLX dissolution from 
LS-3, LS-5 and LS-6 in SGF was 80.28, 34.70 and 39.87 %, 
respectively. Similar sequence was shown in SIF, meaning that 
liquisolid tablets which are formulated with PEG 400 show higher 
dissolution rates than those formulated with PG. In essence, the drug 
may be in a partly dissolved state in the liquid medications of LS-5 
and LS-6 compact. On the other hand, the drug is completely in 





Fig. 13: Dissolution profile of liquisolid compact (LS-1, LS-2, LS-
3, LS-5 and LS-6 in A: 0.1N HCl (pH1.2), and B: phosphate buffer 
(pH 6.8) at 37 ͦ C. 
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Fig. 14: The percentage release of MLX liquisolid compacts (LS-
1A, LS-2A, LS-3A and LS-3B) in A: 0.1 N HCl (pH 1.2), and B: 
phosphate buffer (pH 6.8) at 37 ͦ C. 
 
The effect of liquid vehicle concentration  
The concentration of drug in liquid medication is an important 
aspect in the formulation of liquidsolid compacts. As it was showed 
in figure 13, the increase in drug concentration in liquid medication, 
increase drug release rate [47]. 
Thus, formulation with highest drug concentration in PEG 400 (LS-
3) showed higher drug release than lowest drug concentration (LS-1 
and LS-2) 80.28, 41.07 and 30.38 %,respectively in first 20 min in 
SGF pH 1.2. Also, the formula LS-6 which has high drug 
concentration in PG than LS-5, showed high drug release than lowest 
drug concentration LS-5 by 39.87 and 34.70 %, respectively in first 
20 min in SGF pH 1.2, and these two formula in PG showed lowest 
drug release than formulas with PEG 400. 
LS-3, the liquisolid formula of highest drug concentration in PEG 400 
(30 % w/w), showed the highest dissolution rate among all other 
liquisolid compact. This because as increase of drug concentration lead 
to decrease amount of non volatile solvent used in formula[48]. PEG 
400 facilitated wetting of drug particles by decreasing interfacial 
tension between dissolution medium and tablet surface [49]. 
Effect of dissolution media (pH): 
Comparing the dissolution of MLX in SGF and SIF dissolution media, it 
was found that the drug exhibited higher dissolution rate in SIF as a 
dissolution medium compared to that in SGF as show in figure 13, 14 
and 15. This can be explained on the basis that MLX is a weak acid 
(pKa =1.1) which displays pH-dependent solubility and dissolution. 
The weak acids react with bases in SIF and then exist as ions that are 
ordinarily soluble in water. In the other words, the concentration of 
the drug is high when the drug is mostly ionized. Therefore, its 
dissolution rate increased markedly with increasing the pH [50]. 
The effect of additives on dissolution profile:  
figure (15) show the effect of additive materials that added to liquisolid 
formula as PVP K25 and HPMC E5 this comparism with selected formula 
to show release profile of MLX, the high release of formula LS-3AP and 
LS-3AH compared to LS-3 showed no significant difference (P > 0.05), 
due to increase loading capacity of carrier to MLX under effect of these 
additives and give high release than original formula. 
The effect of encapsulation process on dissolution profile:  
The in-vitro dissolution profiles of MLX (figures 16, 17 and 18) showed 
that there was significant differences (P < 0.05) between release rate 
of selected formulas (LS-3A, LS-3AP and LS-3AH) and its capsule 
formulated of the same formula in SGF dissolution media pH 1.2.  
Figure (16) show the delay release of MLX from capsule first 25 
minutes in comparison with same formula liquisolid tablet which give 
rapid release action. This due to the release from the capsule dosage 
form need to dissolve or lyses of the shell of capsule firstly then release 
it content to media, and this need time to take place which refer to 
disintegration time, as showed in table (5) need more than 25 min to 
completely release it content. While, the liquisolid tablets give the 




Fig. 15: Dissolution profile of liquisolid compact (LS-3AP and 
LS-3AH), DCT and marketed tablet in A: 0.1 N HCl (pH 1.2), and 
B: phosphate buffer (pH 6.8) at 37 ͦ C. 
 
 
Fig. 16: Comparison of the percentage release of MLX liquisolid 
compact (LS-3A) with same formula in encapsulation form in 
0.1 N HCl pH 1.2. 
 
 
Fig. 17: Comparison of the percentage release of MLX liquisolid 
compact (LS-3AP) with same formula in encapsulation form in 
0.1 N HCl pH 1.2. 
Altememy et al. 




Selection of the best formula 
The liquisolid tablet formulated with the PEG 400 at drug 
concentration of 30 % w/w (30 % drug and 70 % PEG 400) with 
excipient ratio (R) =25 is the best formula (LS-3) among all the 
batches of liquisolid tablets; in term of good flow properties, rapid 
disintegration, superior dissolution behaviors and acceptable tablet 
properties. While, the replacement of Aerosil 200 coating material 
with Silica (cab-O-sil) improved these properties as showed in 
formula LS-3A. Whereas, the addition of PVP K 25 as in LS-3AP or 




Fig. 18: Comparison of the percentage release of MLX liquisolid 
compact (LS-3AH) with same formula in encapsulation form in 
0.1 N HCl pH 1.2. 
 
So, the selected formula is LS-3 and its derivatives (LS-3A, LS-3AP 
and LS-3AH). 
LS-3 (having the highest concentration in PEG 400 and R 25) and its 
derivatives showed higher drug release than reference preparation 
equivalent to 15 mg of MLX (mobic 15 mg Boehringer®) in both 
dissolution media as was shown in figure (15). 
One-way ANOVA was used to verify the differences between the mean 
dissolution rates obtained for the selected liquisolid formula (LS-3 and 
its derivatives), DCT and marketed tablet. It is clear that, according to 
ANOVA, there were no significant differences (P> 0.05) between the 
mean dissolution rates obtained for selected LS formula with both DCT 
and mobic® 15 mg tablets in different dissolution media. 
CONCLUSION 
The liquisolid compacts technique can be a promising alternative for 
the formulation of water insoluble drugs, such as meloxicam into 
rapid release tablets. The higher dissolution rates displayed by 
liquisolid compacts may also imply enhanced oral bioavailability due 
to the increased wetting properties and solubility of drug in the 
liquid vehicles. it has been shown that the solubility of the drug in 
the liquid medication of the liquisolid compacts is directly 
proportion to their meloxicam dissolution rates.  
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